Targeted Oncology

Ruta Rao, MD, discusses practical considerations regarding the use of sacituzumab govitecan in patients with relapsed/refractory TNBC.

The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.

Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.

Elizabeth Mittendorf, MD, PhD, and Ruta Rao, MD, present the case of a 48-year-old woman with stage T2N1 TNBC.

Carey Anders, MD, presents a case that focuses on a patient with HER2+ breast cancer and brain metastases.

Experts in the field of breast cancer review the place in therapy for margetuximab.

Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.

The panel of experts in breast cancer discusses the treatment options for a patient with systemic progression of HER2+ disease on T-DM1 and no CNS metastases.

Experts in the management of breast cancer discuss the role of tucatinib in patients with brain metastases.

Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.

Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.

Expert hematologist/oncologists provide thoughts on the potential role of PI3K inhibitors in managing R/R FL and MZL, as well as other diseases.

Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, discuss the role of PI3K inhibitor combination therapy and novel agents on the horizon for the treatment of R/R FL and MZL.

The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.

Carey Anders, MD, and Andrew Seidman, MD, share their recommendations for HER2+ breast cancer recurrence within 12 months of HP.

The panel of experts review the study design and key efficacy data of the KEYNOTE-355 trial.

The panel of experts in breast cancer discuss treatment options when the cancer has metastasized.

Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.

Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.

Ingrid Mayer, MD, MSCI, presents the case of a patient with high-risk HR+/HER2+ breast cancer who develops recurrence after a long disease-free interval.

Ruben Mesa, MD, and panel discuss considerations for optimizing therapy in high risk myelofibrosis.

Experts in myelofibrosis present safety and efficacy data from a clinical trial of fedratinib in patients with high risk myelofibrosis.

Dr Jamile Shammo presents clinical trial data on the efficacy and safety of ruxolitinib in patients with high risk myelofibrosis.

Experts in MPN review data on predictors of response to ruxolitinib in high risk myelofibrosis.

Jamile Shammo, MD, reviews prognostic models in myelofibrosis.

Dr Jamile Shammo reviews the case of a 72-year-old man with primary myelofibrosis.

Targeting different pathways may dramatically reduce the risk of resistance emergence and improve outcomes.

Experts in the management of breast cancer review some trials leading to the future of personalized treatment for HER2+ breast cancer.

Andrew Seidman, MD, follows the patient after TCHP therapy and discusses the risk of recurrence with the experts.

Ingrid Mayer, MD, MSCI, and panel share the benefits of subcutaneous HP instead of IV HP therapy, particularly for the patients’ quality of life.